Silexion Therapeutics shares are trading lower. The company announced initiation of its Phase 2/3 clinical trial of SIL204, lead siRNA product candidate, at TASMC.

Benzinga Newsdesk www.benzinga.com Neutral 43.6%

Neg 0% Neu 43.6% Pos 0%

Comments

No comments yet. Be the first!